# A Study of the Effectiveness and Safety of Treatment With Epoetin Alfa on Hemoglobin Levels, Red Blood Cell Transfusions, and Quality of Life in Patients With Cancer Receiving Platinum-containing Chemotherapy

> **NCT00283465** · PHASE4 · COMPLETED · sponsor: **Janssen-Cilag B.V.** · enrollment: 316 (actual)

## Conditions studied

- Anemia
- Neoplasm

## Interventions

- **DRUG:** Epoetin alfa

## Key facts

- **NCT ID:** NCT00283465
- **Lead sponsor:** Janssen-Cilag B.V.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE4
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 1999-11
- **Primary completion:** —
- **Final completion:** 2004-04
- **Target enrollment:** 316 (ACTUAL)
- **Last updated:** 2011-01-14


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00283465

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00283465, "A Study of the Effectiveness and Safety of Treatment With Epoetin Alfa on Hemoglobin Levels, Red Blood Cell Transfusions, and Quality of Life in Patients With Cancer Receiving Platinum-containing Chemotherapy". Retrieved via AI Analytics 2026-06-09 from https://api.ai-analytics.org/clinical/NCT00283465. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*